Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tiara Hypolite

Infectious Disease Fort Myers, FL Medical Doctor

NPI 1831486489 CMS profile 2790400

2780 Cleveland Ave Ste 809, Fort Myers, FL 33901

Open in the dashboard

General payments

$382

18 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tiara Hypolite of Fort Myers, FL is reported in the CMS Open Payments database as having received $382 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33 1
2023 General $18 1
2022 General $201 10
2021 General $50 2
2020 General $48 2
2019 General $32 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tiara Hypolite
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Tiara Hypolite were reported at $33. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Tiara Hypolite Infectious Disease median Middle half National median
2019 $32 $190 $60–$862 $163
2020 $48 $124 $32–$606 $114
2021 $50 $148 $38–$905 $132
2022 $201 $166 $50–$834 $149
2023 $18 $171 $57–$787 $160
2024 $0 $176 $52–$752 $164
2025 $33 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shionogi Inc $93 4 payments
  2. Allergan Inc. $55 3 payments
  3. Paratek Pharmaceuticals, Inc. $50 2 payments
  4. Gilead Sciences, Inc. $49 2 payments
  5. AbbVie, Inc. $46 3 payments
  6. Philips Electronics North America Corporation $46 2 payments
  7. Pfizer Inc. $26 1 payment
  8. Janssen Biotech, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $382 18 payments
Products named General payments · program years 2019–2025
  1. Fetroja $93 4 payments
  2. AVYCAZ $86 5 payments
  3. NUZYRA $50 2 payments
  4. (4942) CoughAssist 2 $28 1 payment
  5. ELIQUIS $26 1 payment
  6. (8874) inCourage $18 1 payment
  7. SYMTUZA $17 1 payment
  8. DALVANCE $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

175

Median for Infectious Disease: 268

Drug cost

$37,676

Median for Infectious Disease: $217,595

Branded share of claims

31.4%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Daptomycin Generic 43 $19,861
Piperacillin-Tazobactam Piperacillin Sodium/Tazobactam Brand 22 $6,318
Ertapenem Ertapenem Sodium Brand 18 $5,685
Cefepime Hcl Generic 23 $3,049
Cefadroxil Generic 12 $1,002
Cefazolin Sodium Generic 15 $932
Doxycycline Hyclate Generic 27 $595
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 15 $234

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$104,078

Medicare's payments for the services billed

Medicare patients

293

Average age 75

Services billed

1,086

146 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 55%
Diabetes 48%
Heart failure 45%
Chronic kidney disease 44%
Depression 43%
Atrial fibrillation 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record